Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia.
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Patrys's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PAB's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PAB underperformed the Australian Biotechs industry which returned 55.2% over the past year.
Return vs Market: PAB underperformed the Australian Market which returned -18.8% over the past year.
Price Volatility Vs. Market
How volatile is Patrys's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHow Much Did Patrys Limited's (ASX:PAB) CEO Pocket Last Year?
1 month ago | Simply Wall StIntroducing Patrys (ASX:PAB), The Stock That Zoomed 200% In The Last Three Years
2 months ago | Simply Wall StWe Think Patrys (ASX:PAB) Can Easily Afford To Drive Business Growth
Is Patrys undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate PAB's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate PAB's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: PAB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: PAB is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PAB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PAB is overvalued based on its PB Ratio (2.4x) compared to the AU Biotechs industry average (2.4x).
How is Patrys forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Patrys has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Patrys's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Patrys competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Patrys performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PAB is currently unprofitable.
Growing Profit Margin: PAB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PAB is unprofitable, but has reduced losses over the past 5 years at a rate of 42.8% per year.
Accelerating Growth: Unable to compare PAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.5%).
Return on Equity
High ROE: PAB has a negative Return on Equity (-52.02%), as it is currently unprofitable.
How is Patrys's financial position?
Financial Position Analysis
Short Term Liabilities: PAB's short term assets (A$5.8M) exceed its short term liabilities (A$516.3K).
Long Term Liabilities: PAB's short term assets (A$5.8M) exceed its long term liabilities (A$19.3K).
Debt to Equity History and Analysis
Debt Level: PAB is debt free.
Reducing Debt: PAB has not had any debt for past 5 years.
Inventory Level: PAB has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if PAB's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PAB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PAB has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 31.9% each year.
What is Patrys's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PAB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PAB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PAB's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Dr. James A. Campbell, BSc(Hons), PhD, MBA, GAICD serves as Chief Executive Officer and Managing Director for Patrys Limited since April 13, 2015. Dr. Campbell serves as Principal of Gemini Biotechnology. ...
CEO Compensation Analysis
Compensation vs Market: James's total compensation ($USD310.24K) is about average for companies of similar size in the Australian market ($USD245.57K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Patrys Limited's company bio, employee growth, exchange listings and data sources
- Name: Patrys Limited
- Ticker: PAB
- Exchange: ASX
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$12.860m
- Shares outstanding: 1.07b
- Website: https://www.patrys.com
Number of Employees
- Patrys Limited
- 100 Albert Road
- Level 4
- South Melbourne
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PAB||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||Jul 2007|
|PAB||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||Jul 2007|
Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates live cell nuclei and inhibits mechanisms of DNA repair in target cancer cells. The company also focuses on developing PAT-DX1 as a treatment for metastatic triple negative breast cancer and glioblastoma. In addition, it engages in developing PAT-SC1’s target/antigen CD55PAT-SC1, an isoform of the membrane-bound CD55 for the treatment of gastric cancer. Patrys Limited was founded in 2006 and is based in South Melbourne, Australia.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/31 10:43|
|End of Day Share Price||2020/03/31 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.